Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis
作者:Zhijun Cao、Yuxia Liu、Siliang Chen、Wenxin Wang、Zhongcheng Yang、Ya Chen、Shixuan Jiao、Wanqiu Huang、Lianru Chen、Lidan Sun、Zheng Li、Luyong Zhang
DOI:10.1016/j.bcp.2023.115742
日期:2023.9
compound 1 with a novel scaffold by high-throughput screening in our in-house library. After a comprehensive structure–activity relationship study, the optimal compound 24 was discovered as an efficient and highly selective hCES2 inhibitor (hCES2: IC50 = 6.72 μM; hCES1: IC50 > 100 μM). Further enzyme kinetics study indicated that compound 24 is a reversible inhibitor of hCES2 with competitive inhibition
人羧酸酯酶 2 (hCES2) 是一种将伊立替康代谢为 SN-38 的酶,SN-38 是一种有毒代谢物,被认为是副作用(致命性迟发性腹泻)的重要来源。hCES2抑制剂可以阻断伊立替康在肠道中的水解,从而减少肠道SN-38的暴露,从而可能缓解伊立替康相关的腹泻。然而,现有的hCES2抑制剂(洛哌丁胺除外)由于缺乏有效性或可接受的安全性而未用于临床应用。因此,迫切需要开发更有效、更安全的治疗迟发性腹泻的药物。本研究通过我们内部图书馆的高通量筛选鉴定了具有新型支架的先导化合物1 。经过全面的构效关系研究,发现最佳化合物24是一种高效且高选择性的hCES2抑制剂(hCES2:IC 50 = 6.72 μM;hCES1:IC 50 > 100 μM)。进一步的酶动力学研究表明,化合物24是hCES2的可逆抑制剂,具有竞争性抑制模式(Ki = 6.28 μM)。细胞实验表明,化合物24可以降低活细胞中hCES2的水平(IC